Tokyo Tape
Sign in
← OncoTherapy Science

Quarterly report · Q2

4564.TEDINET S100PGWR
Period2022-04-01 → 2022-09-30
Filed2022-11-07
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥515m2022-04-01 → 2022-09-30Cons.Net sales
Revenue¥241m2021-04-01 → 2021-09-30Cons.Net sales
Operating income−¥618m2022-04-01 → 2022-09-30Cons.Operating income
Operating income−¥949m2021-04-01 → 2021-09-30Cons.Operating income
Ordinary income−¥644m2022-04-01 → 2022-09-30Cons.Ordinary income
Ordinary income−¥2.1bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income−¥952m2021-04-01 → 2021-09-30Cons.Ordinary income
Profit before tax−¥613m2022-04-01 → 2022-09-30Cons.Income before income taxes
Profit before tax−¥1.2bn2021-04-01 → 2021-09-30Cons.Income before income taxes
Net income (owners)−¥614m2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)−¥2.6bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥1.2bn2021-04-01 → 2021-09-30Cons.Profit loss attributable to owners of parent
Net income−¥614m2022-04-01 → 2022-09-30Cons.Profit loss
Net income−¥1.2bn2021-04-01 → 2021-09-30Cons.Profit loss
Total assets¥1.7bnat 2022-09-30Cons.Assets
Total assets¥2.7bnat 2022-03-31Cons.Assets
Total assets¥3.7bnat 2021-09-30Cons.Total assets (5-year summary)
Total liabilities¥340mat 2022-09-30Cons.Liabilities
Total liabilities¥705mat 2022-03-31Cons.Liabilities
Net assets / equity¥1.3bnat 2022-09-30Cons.Net assets
Net assets / equity¥2.0bnat 2022-03-31Cons.Net assets
Net assets / equity¥3.1bnat 2021-09-30Cons.Net assets (5-year summary)
Cash and deposits¥1.3bnat 2022-09-30Cons.Cash and deposits
Cash and deposits¥1.8bnat 2022-03-31Cons.Cash and deposits
Cash & equivalents¥1.3bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥1.8bnat 2022-03-31Cons.Cash and cash equivalents
Cash & equivalents¥3.1bnat 2021-09-30Cons.Cash and cash equivalents
Cash & equivalents¥2.9bnat 2021-03-31dCons.Cash and cash equivalents
Operating cash flow−¥517m2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Operating cash flow−¥2.1bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow−¥1.0bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥7m2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥468m2021-04-01 → 2022-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥25m2021-04-01 → 2021-09-30Cons.Net cash provided by used in investment activities
Financing cash flow¥1.5bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥1.3bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥-3.192022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-1.742022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-13.722021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-6.742021-04-01 → 2021-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-3.722021-07-01 → 2021-09-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio76.3%at 2022-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio70.6%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio81.2%at 2021-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 29
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥111,000
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥111,000
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥188m
jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥507m
jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥507m
jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segmentsegment profit2022-04-01 → 2022-09-30−¥48m
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue2022-04-01 → 2022-09-30¥8m
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue external2022-04-01 → 2022-09-30¥8m
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥111,000
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentsegment profit2022-04-01 → 2022-09-30−¥382m
—segment totalrevenue2022-04-01 → 2022-09-30¥515m
—segment totalrevenue external2022-04-01 → 2022-09-30¥515m
—segment totalrevenue intersegment2022-04-01 → 2022-09-30¥111,000
—segment totalsegment profit2022-04-01 → 2022-09-30−¥430m
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-09-30−¥8m
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-09-30−¥8m
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-09-30−¥195m
jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥243m
jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥234m
jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥8m
jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segmentsegment profit2021-04-01 → 2021-09-30−¥63m
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue2021-04-01 → 2021-09-30¥6m
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue external2021-04-01 → 2021-09-30¥6m
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥111,000
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentsegment profit2021-04-01 → 2021-09-30−¥691m
—segment totalrevenue2021-04-01 → 2021-09-30¥249m
—segment totalrevenue external2021-04-01 → 2021-09-30¥241m
—segment totalrevenue intersegment2021-04-01 → 2021-09-30¥8m
—segment totalsegment profit2021-04-01 → 2021-09-30−¥754m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 443
ItemContextValueUnit
Other caPrior1YearInstant113764000JPY
Other caCurrentQuarterInstant92899000JPY
Current assetsPrior1YearInstant2600551000JPY
Current assetsCurrentQuarterInstant1597391000JPY
BuildingsPrior1YearInstant568281000JPY
BuildingsCurrentQuarterInstant534688000JPY
Accumulated depreciation and impairment loss buildingsPrior1YearInstant-568281000JPY
Accumulated depreciation and impairment loss buildingsCurrentQuarterInstant-534688000JPY
Buildings netPrior1YearInstant－JPY
Buildings netCurrentQuarterInstant－JPY
Machinery and equipmentPrior1YearInstant65503000JPY
Machinery and equipmentCurrentQuarterInstant65503000JPY
Accumulated depreciation and impairment loss machinery and equipmentPrior1YearInstant-65503000JPY
Accumulated depreciation and impairment loss machinery and equipmentCurrentQuarterInstant-65503000JPY
Machinery and equipment netPrior1YearInstant－JPY
Machinery and equipment netCurrentQuarterInstant－JPY
Tools furniture and fixturesPrior1YearInstant1161040000JPY
Tools furniture and fixturesCurrentQuarterInstant1159619000JPY
Accumulated depreciation and impairment loss tools furniture and fixturesPrior1YearInstant-1161022000JPY
Accumulated depreciation and impairment loss tools furniture and fixturesCurrentQuarterInstant-1159619000JPY
Tools furniture and fixtures netPrior1YearInstant17000JPY
Tools furniture and fixtures netCurrentQuarterInstant－JPY
Property plant and equipmentPrior1YearInstant17000JPY
Property plant and equipmentCurrentQuarterInstant－JPY
Guarantee deposits ioaPrior1YearInstant84630000JPY
Guarantee deposits ioaCurrentQuarterInstant84630000JPY
Investments and other assetsPrior1YearInstant84630000JPY
Investments and other assetsCurrentQuarterInstant84630000JPY
Noncurrent assetsPrior1YearInstant84648000JPY
Noncurrent assetsCurrentQuarterInstant84630000JPY
AssetsPrior1YearInstant2685199000JPY
AssetsCurrentQuarterInstant1682021000JPY
Accounts payable otherPrior1YearInstant422113000JPY
Accounts payable otherCurrentQuarterInstant131497000JPY
Contract liabilitiesPrior1YearInstant22268000JPY
Contract liabilitiesCurrentQuarterInstant－JPY
Income taxes payablePrior1YearInstant136533000JPY
Income taxes payableCurrentQuarterInstant68192000JPY
Asset retirement obligations clPrior1YearInstant3678000JPY
Asset retirement obligations clCurrentQuarterInstant61997000JPY
Other clPrior1YearInstant20330000JPY
Other clCurrentQuarterInstant34019000JPY
Current liabilitiesPrior1YearInstant604923000JPY
Current liabilitiesCurrentQuarterInstant295706000JPY
Deferred tax liabilitiesPrior1YearInstant338000JPY
Deferred tax liabilitiesCurrentQuarterInstant－JPY
Asset retirement obligations nclPrior1YearInstant99703000JPY
Asset retirement obligations nclCurrentQuarterInstant43991000JPY
Noncurrent liabilitiesPrior1YearInstant100041000JPY
Noncurrent liabilitiesCurrentQuarterInstant43991000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-03-31pass rounding
balance sheet identityconsolidated 2022-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass